增殖性糖尿病视网膜病变中治疗方式及失访与牵拉性视网膜脱离的关联
本嵌套病例对照研究利用商业及Medicare Advantage医保理赔数据库2000年1月1日至2021年6月30日的数据,将214例进展为牵拉性视网膜脱离(TRD)的增殖性糖尿病视网膜病变(PDR)患者按最多5:1匹配978例对照。调整分析显示,仅玻璃体腔注射(IVI)与仅全视网膜光凝(PRP)相比TRD比值无显著差异,6个月及以上失访(LTFU)与无失访相比亦无显著差异。作者结论认为IVI-only治疗或6个月及以上LTFU未见TRD风险增加。
要点
- 仅IVI与仅PRP相比,TRD的调整OR为0.56(95%CI 0.27-1.14),无显著差异。
- 接受两种治疗者较仅PRP者TRD比值更高(aOR 2.33;95%CI 1.21-4.48)。
- 6个月及以上LTFU与无LTFU相比TRD比值无显著差异(aOR 0.72;95%CI 0.49-1.07;P=.11)。
核心结论
- 作者结论认为,本病例对照分析结果提示仅IVI治疗或6个月及以上LTFU与TRD风险增加无关,支持其他研究的结果。
- 作者同时指出,PDR患者中LTFU率仍居高不下,无论采用何种治疗方案,均可导致实质性视力丧失。
研究设计与样本
- 嵌套病例对照研究,数据来自去标识化的商业及Medicare Advantage医保理赔数据库,时间为2000年1月1日至2021年6月30日。
- 纳入PDR患者,进展为TRD者按最多5:1比例与非TRD对照匹配;排除在计划内2年或以下、非糖尿病性视网膜病变史、玻璃体出血、既往视网膜脱离或任何其他有手术指征诊断者。
- 统计分析于2022年1月至5月进行。
主要发现
- 共纳入214例PDR合并TRD患者(平均[SD]年龄55.6[12.4]岁;女性115例[53.7%]),匹配978例仅PDR对照(平均[SD]年龄65.6[11.3]岁;女性507例[51.8%])。
- TRD组中仅激光治疗69例(32.2%)、仅注射治疗17例(7.9%)、两者均用39例(18.2%)、无既往治疗89例(41.6%)。
- 仅PDR组中仅激光治疗207例(21.2%)、仅注射治疗83例(8.5%)、两者均用57例(5.8%)、未治疗631例(64.5%)。
- 调整分析显示,仅注射治疗与仅激光治疗相比TRD比值无差异(aOR 0.56;95%CI 0.27-1.14)。
- 接受两种治疗者较仅激光治疗者TRD比值更高(aOR 2.33;95%CI 1.21-4.48),未治疗者TRD比值更低(aOR 0.46;95%CI 0.29-0.71;治疗类别P<.001)。
关键数值与推荐
- 主要暴露为既往治疗(PRP、IVI、两者)及任何6个月及以上未接受眼科诊疗的时期。
- 主要结局指标为仅IVI与PRP相比及6个月及以上LTFU对TRD发生的OR。
- 仅注射治疗 vs 仅激光治疗:aOR 0.56(95%CI 0.27-1.14)。
- 两种治疗均用 vs 仅激光治疗:aOR 2.33(95%CI 1.21-4.48)。
- 未治疗 vs 仅激光治疗:aOR 0.46(95%CI 0.29-0.71;治疗类别P<.001);6个月及以上LTFU vs 无LTFU:aOR 0.72(95%CI 0.49-1.07;P=.11)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The association of proliferative diabetic retinopathy (PDR) interventions of panretinal photocoagulation (PRP) and intravitreal injections (IVIs) with tractional retinal detachment (TRD) is unclear. OBJECTIVES: To determine whether different treatment types or a 6-month or longer period of loss to follow-up (LTFU) is associated with TRD. DESIGN, SETTING, AND PARTICIPANTS: This nested case-control study included data from January 1, 2000, to June 30, 2021, of patients with PDR. Those who progressed to TRD were matched to non-TRD controls up to a 5:1 ratio. Exclusion criteria included 2 or fewer years in the plan, history of nondiabetic retinopathy, vitreous hemorrhage, previous RD, or any other surgically indicated diagnosis. Patient data were obtained from a deidentified commercial and Medicare Advantage medical claims database. Statistical analysis was performed from January to May 2022. EXPOSURES: Primary exposures of interest were prior treatment (PRP, IVI, both) and any period of 6 months or longer in which the patient received no eye care. MAIN OUTCOMES AND MEASURES: Odds ratios (ORs) of IVI only compared with PRP and 6-month or longer LTFU on development of TRD. RESULTS: After application of inclusion and exclusion criteria, a total of 214 patients (mean [SD] age, 55.6 [12.4] years; 115 female [53.7%]) with PDR and TRD were matched to 978 controls (mean [SD] age, 65.6 [11.3] years; 507 female [51.8%]) with only PDR. Among patients with TRD, 69 (32.2%) were treated with laser only, 17 (7.9%) were treated with injection only, 39 (18.2%) were treated with both, and 89 (41.6%) had no prior treatment. Among patients in the PDR-only group, 207 (21.2%) received laser only, 83 (8.5%) received injection only, 57 (5.8%) received both, and 631 (64.5%) received no treatment. After adjusted analysis, no difference in odds of TRD for patients who received injection only compared with patients who received laser only was found (adjusted OR [aOR], 0.56; 95% CI, 0.27-1.14). Patients who received both treatments had higher odds of TRD compared with those who received laser only (aOR, 2.33; 95% CI, 1.21-4.48), and patients who had no treatment had lower odds of TRD (aOR, 0.46; 95% CI, 0.29-0.71; P < .001 for treatment category). Similarly, no difference was seen in the odds of TRD between those with LTFU for 6 months or longer and those without LTFU (aOR, 0.72; 95% CI, 0.49-1.07; P = .11). CONCLUSIONS AND RELEVANCE: Results of this case-control analysis suggest that there is no increased risk of TRD associated with IVI-only treatment or with 6-month or longer periods of LTFU, which supports the findings of other investigations. Nonetheless, LTFU rates continue to remain high in patients with PDR, which can contribute to substantial vision loss regardless of treatment regimen.
引用
- Tsui JC, Yu Y, VanderBeek BL, et al. Association of Treatment Type and Loss to Follow-up With Tractional Retinal Detachment in Proliferative Diabetic Retinopathy. JAMA Ophthalmol. 2023. PMID: 36454552. doi:10.1001/jamaophthalmol.2022.4942
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。